OBJECTIVES: The Pro12Ala variant in the peroxisome proliferator-activated receptor gamma (PPARG) gene has been associated with diabetes and several cancers. This pilot study tested for the association between Pro12Ala and pancreatic cancer risk in a high-risk sample of smokers. METHODS: A nested case-control study was conducted in 83 incident cases of pancreatic cancer and 166 matched controls originally recruited into a cohort chemoprevention study of lung cancer. Associations between Pro12Ala and pancreatic cancer risk were measured using conditional logistic regression. RESULTS: Carriers of the G allele (Ala) of the Pro12Ala variant had a borderline increased relative risk of pancreatic cancer compared with homozygous carriers of the C allele (Pro), with an odds ratio of 1.79 (95% confidence interval [CI], 0.96-3.33; P=0.06). Among subjects randomized to high-dose vitamin A, the odds ratio was 2.80 (95% CI, 1.16-6.74; P=0.02) versus 1.20 (95% CI, 0.45-3.23; P=0.71) in the placebo group. A haplotype including Pro12Ala was also significantly associated with pancreatic cancer risk in all subjects and in subjects randomized to vitamin A. CONCLUSIONS: This analysis presents the first evidence that PPARG may be associated with pancreatic cancer risk, and this candidate gene should be investigated in future, larger studies.
OBJECTIVES: The Pro12Ala variant in the peroxisome proliferator-activated receptor gamma (PPARG) gene has been associated with diabetes and several cancers. This pilot study tested for the association between Pro12Ala and pancreatic cancer risk in a high-risk sample of smokers. METHODS: A nested case-control study was conducted in 83 incident cases of pancreatic cancer and 166 matched controls originally recruited into a cohort chemoprevention study of lung cancer. Associations between Pro12Ala and pancreatic cancer risk were measured using conditional logistic regression. RESULTS: Carriers of the G allele (Ala) of the Pro12Ala variant had a borderline increased relative risk of pancreatic cancer compared with homozygous carriers of the C allele (Pro), with an odds ratio of 1.79 (95% confidence interval [CI], 0.96-3.33; P=0.06). Among subjects randomized to high-dose vitamin A, the odds ratio was 2.80 (95% CI, 1.16-6.74; P=0.02) versus 1.20 (95% CI, 0.45-3.23; P=0.71) in the placebo group. A haplotype including Pro12Ala was also significantly associated with pancreatic cancer risk in all subjects and in subjects randomized to vitamin A. CONCLUSIONS: This analysis presents the first evidence that PPARG may be associated with pancreatic cancer risk, and this candidate gene should be investigated in future, larger studies.
Authors: L Fajas; D Auboeuf; E Raspé; K Schoonjans; A M Lefebvre; R Saladin; J Najib; M Laville; J C Fruchart; S Deeb; A Vidal-Puig; J Flier; M R Briggs; B Staels; H Vidal; J Auwerx Journal: J Biol Chem Date: 1997-07-25 Impact factor: 5.157
Authors: V Tavares; R D C Hirata; A C Rodrigues; O Monte; J E N Salles; N Scalissi; A C Speranza; M H Hirata Journal: Diabetes Obes Metab Date: 2005-09 Impact factor: 6.577
Authors: Megan Dann Fesinmeyer; Melissa A Austin; Christopher I Li; Anneclaire J De Roos; Deborah J Bowen Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-07 Impact factor: 4.254
Authors: S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx Journal: Nat Genet Date: 1998-11 Impact factor: 38.330
Authors: D T Silverman; M Schiffman; J Everhart; A Goldstein; K D Lillemoe; G M Swanson; A G Schwartz; L M Brown; R S Greenberg; J B Schoenberg; L M Pottern; R N Hoover; J F Fraumeni Journal: Br J Cancer Date: 1999-08 Impact factor: 7.640
Authors: Pui-yee Fong; Megan D Fesinmeyer; Emily White; Federico M Farin; Sengkeo Srinouanprachanh; Zahra Afsharinejad; Margaret T Mandelson; Teresa A Brentnall; Matt J Barnett; Gary E Goodman; Melissa A Austin Journal: J Gastrointest Cancer Date: 2010-09
Authors: Anna E Prizment; Myron Gross; Laura Rasmussen-Torvik; James M Peacock; Kristin E Anderson Journal: Pancreas Date: 2012-01 Impact factor: 3.327
Authors: Melissa A Austin; Elena Kuo; Stephen K Van Den Eeden; Margaret T Mandelson; Teresa A Brentnall; Aruna Kamineni; John D Potter Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-08-21 Impact factor: 4.254